
    
      An interventional, double-blind, randomized, intracohort placebo-controlled design will be
      used to test safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in
      36 patients ≥ 18 and ≤ 70 years of age with documented dcSS. There will up a screening period
      of up to 28 days, 84 days treatment period, and 28 days follow-up.
    
  